| Literature DB >> 31136173 |
Sven Verdonck1, Szu-Yuan Pu2, Fiona J Sorrell3, Jon M Elkins3,4, Mathy Froeyen1, Ling-Jie Gao1, Laura I Prugar5, Danielle E Dorosky5, Jennifer M Brannan5, Rina Barouch-Bentov2, Stefan Knapp3,6, John M Dye5, Piet Herdewijn1, Shirit Einav2, Steven De Jonghe1.
Abstract
There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola. Adaptor-associated kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-associated host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses. Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells. Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analogue, yielding novel pyrrolo[2,3- b]pyridines with high AAK1 affinity. The optimized compounds demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus. These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31136173 PMCID: PMC6825517 DOI: 10.1021/acs.jmedchem.9b00136
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446